FibroBiologics Presents Novel Thymus Organoid Platform to Combat Age-Related Immune Decline at Keystone Symposia on Aging and Immunity
FibroBiologics, Inc. (FBLG)
Company Research
Source: GlobeNewswire
HOUSTON, April 10, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced preclinical data supporting the potential of its proprietary thymic organoid platform to reverse age-related immune decline by restoring thymic function lost over time. The findings were presented at the Keystone Symposia on Aging and Immunity. A link to the poster can be found here. The thymus is the primary site of T cell development, responsible for producing and educating the immune cells that underpin adaptive immunity, the body's ability to recognize and respond to specific threats including cancer, pathogens, and aberrant self-cells. Thymic function begins declining early in life and accelerates with age, a process known as thymic
Show less
Read more
Impact Snapshot
Event Time:
FBLG
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FBLG alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FBLG alerts
High impacting FibroBiologics, Inc. news events
Weekly update
A roundup of the hottest topics
FBLG
News
- FibroBiologics Compliant with All Nasdaq Listing RequirementsGlobeNewswire
- FibroBiologics (FBLG) had its "buy" rating reaffirmed by HC Wainwright.MarketBeat
- FibroBiologics (FBLG) was upgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=FBLG&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> to "sell".MarketBeat
- FibroBiologics Announces Closing of $3 Million Public OfferingGlobeNewswire
- FibroBiologics Announces Pricing of $3 Million Public Offering [Yahoo! Finance]Yahoo! Finance
FBLG
Earnings
- 5/14/25 - Miss
FBLG
Sec Filings
- 4/22/26 - Form PRE
- 4/20/26 - Form 8-K
- 4/17/26 - Form 8-K
- FBLG's page on the SEC website